|
TGIF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.27595720048157E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.11242176265614E-12 |
| Normal-vs-Stage2 |
1.53420000037485E-08 |
| Normal-vs-Stage3 |
6.88338275267597E-15 |
| Normal-vs-Stage4 |
7.72704122908863E-12 |
| Stage1-vs-Stage2 |
6.264400E-01 |
| Stage1-vs-Stage3 |
1.980320E-02 |
| Stage1-vs-Stage4 |
3.971600E-02 |
| Stage2-vs-Stage3 |
2.351200E-01 |
| Stage2-vs-Stage4 |
1.929990E-01 |
| Stage3-vs-Stage4 |
7.728200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.88578058618805E-14 |
| Normal-vs-AfricanAmerican |
8.39120000000193E-05 |
| Normal-vs-Asian |
9.41970001999692E-09 |
| Caucasian-vs-AfricanAmerican |
3.610000E-01 |
| Caucasian-vs-Asian |
7.042100E-02 |
| AfricanAmerican-vs-Asian |
9.937600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.88133969408955E-12 |
| Normal-vs-Female |
1.65778502037028E-12 |
| Male-vs-Female |
9.901200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.16899831428918E-11 |
| Normal-vs-Age(41-60Yrs) |
1.91846538655227E-12 |
| Normal-vs-Age(61-80Yrs) |
1.85229609428461E-12 |
| Normal-vs-Age(81-100Yrs) |
3.441300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.503400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.745700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.415000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.108200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.826400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.730600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.965900E-04 |
| Classical-VS-Follicular |
8.916800E-01 |
| Classical-VS-Other |
4.113400E-01 |
| Classical-VS-Normal |
4.94204677181642E-12 |
| Tall-VS-Follicular |
1.036490E-03 |
| Tall-VS-Other |
2.882800E-01 |
| Tall-VS-Normal |
1.63302704692114E-12 |
| Follicular-VS-Other |
5.044400E-01 |
| Follicular-VS-Normal |
4.23659995973935E-09 |
| Other-VS-Normal |
1.018180E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.51578790922258E-12 |
| Normal-vs-N1 |
7.7715611723761E-16 |
| N0-vs-N1 |
1.999060E-03 |
|
|
